RecruitingNCT03225820
Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
Sponsor
University of Chicago
Enrollment
1,000 participants
Start Date
Nov 9, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients must be at least 18 years of age.
- Patients must self-identify as African American
Exclusion Criteria4
- Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
- Patients with known active or prior leukemia.
- Inability to understand and give informed consent to participate.
- For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance <30 mL/min34.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03225820